"Maximizing access to lifesaving hepatitis C treatment is a priority for WHO," says Dr Gottfried Hirnschall, Director of WHO's Department of HIV and Global Hepatitis Programme.
15443
“一些国家开始取得的重要进展令人鼓舞。
"It is encouraging to see countries starting to make important progress.
15444
然而大多数人依然无法获得药物。”
However, access still remains beyond the reach for most people."
A new WHO report, Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers , released today shows how political will, civil society advocacy and pricing negotiations are helping address hepatitis C, a disease which kills almost 700 000 people annually and places a heavy burden on health systems’ capacities and resources.
"Licensing agreements and local production in some countries have gone a long way to make these treatments more affordable," says Dr Suzanne Hill, WHO Director for Essential Medicines and Health Products.
15447
比如，埃及三个月治疗价格从2014年的900美元降到了2016年的不足200美元。
For example, the price of a three-month treatment in Egypt dropped from US$900 in 2014 to less than US$200 in 2016.
15448
“但各国支付的数额之间依然存在巨大差别。
"But there are still huge differences between what countries are paying.
15449
有些丙肝负担最大的中等收入国家依然要支付十分高昂的费用。
Some middle-income countries, which bear the largest burden of hepatitis C, are still paying very high prices.
15450
世卫组织正在就此以及其它昂贵药物制定新的定价模式，以增进所有国家获得所有基本药物。”
WHO is working on new pricing models for these, and other expensive medicines, in order to increase access to all essential medicines in all countries," says Dr Hill.